PALI-2108

PALI-2108 is a novel, orally administered, colon-targeted prodrug developed for the treatment of ulcerative colitis. It is designed to be activated specifically in the colon by bacterial β-glucuronidase, which cleaves its galactose sugar moiety and releases the active phosphodiesterase-4 (PDE4) inhibitor, PALI-0008. This targeted delivery minimizes systemic exposure and reduces central nervous system toxicity commonly associated with systemic PDE4 inhibitors. Preclinical studies have shown that PALI-2108 reduces colitis symptoms in animal models more effectively than standard treatments and other PDE4 inhibitors, with a favorable safety profile and no observed CNS toxicity. Early clinical data indicate that it is safe and well tolerated in healthy volunteers at multiple dose levels. The drug’s mechanism involves local inhibition of PDE4B expression in colonic tissue, leading to increased intracellular cAMP levels and reduced inflammation[1][2][3][4][5][6][7][8].